Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139056 · ClinicalTrials.gov registry record · Phase 1
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
A Phase 1 study of Currently Only Enrolling Glioblastoma Patients at First Recurrence, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT05139056 is a Phase 1 study of Currently Only Enrolling Glioblastoma Patients at First Recurrence that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 36 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT05139056, a Phase 1 study of Currently Only Enrolling Glioblastoma Patients at First Recurrence, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.
Conditions Studied
Interventions
- PROCEDURE Resection
- BIOLOGICAL Neural Stem Cells-expressing CRAd-S-pk7
Study Locations (4)
California
- City of Hope Medical Center - Duarte
- Standford University - Stanford
Illinois
- Northwestern University - Chicago
North Carolina
- Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2026-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05139056
The ClinicalTrials.gov registry entry for NCT05139056 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Currently Only Enrolling Glioblastoma Patients at First Recurrence appearing as the primary indexed condition, and to 2 interventions - of which Resection is the first listed.
NCT05139056 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05139056 about?
NCT05139056 is a clinical study titled "Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas". This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple dose...
What is the current status of trial NCT05139056?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-05-02. Estimated completion is 2026-08-07.
What conditions does trial NCT05139056 study?
This clinical trial studies the following conditions: Currently Only Enrolling Glioblastoma Patients at First Recurrence.
What interventions are being tested in trial NCT05139056?
The interventions under investigation include: Resection (PROCEDURE), Neural Stem Cells-expressing CRAd-S-pk7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05139056?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05139056 being conducted?
This trial has 4 study locations across California, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.